Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FMMU, Biostar sign research cooperation agreement
FMMU is one of China’s military medical universities and research centers which aims to advance military medicine. Biostar chairman and CEO Ronghua Wang said Biostar will work with
FMMU is one of China’s military medical universities and research centers which aims to advance military medicine. Biostar chairman and CEO Ronghua Wang said Biostar will work with
The FDA approval will allow Genzyme to begin the process of returning patients to full dosing (1mg/kg) levels. According to the company, all patients in the US currently
The randomised study has evaluated the safety and efficacy of standard-dose ZEVALIN 14 days prior to ASCT, followed by high-dose BEAM chemotherapy (Z-BEAM) and ASCT in refractory/relapsed aggressive
The ANDA filing involved contributions from both Perrigo and Impax who will share costs and benefits of this project. Astepro Nasal Spray is a prescription medicine for people
As Sanguine increases its presence on the biomarker development front, the company’s clients will demand bioassay development services, and TGA is now well positioned to receive a larger
The Phase III pivotal study of TR701-112 is the first of two pivotal Phase II trials designed to support the filing of a NDA with the FDA as
Through the agreement with UH Bristol, PAREXEL expands alliance network to support early phase patient studies. UH Bristol, a provider of medical and dental teaching, is a research
The data has suggested that repeated cycles of fractionated doses of clivatuzumab tetraxetan, labeled with yttrium-90 (90Y) and given in combination with gemcitabine, demonstrated therapeutic activity in pancreatic
The new patent has a scheduled expiry date in 2028, not including any potential regulatory extensions. The HuCAL-derived, fully human antibody is currently being tested in a Phase
WEP has developed two proprietary biopolymer technologies, PolyPEG and GlycoPol. WEP has agreements with global pharmaceutical and biotechnology companies for the evaluation of PolyPEG or GlycoPol and the